These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28221251)

  • 1. Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease.
    Sexton KA; Walker JR; Graff LA; Bernstein MT; Beatie B; Miller N; Sargent M; Targownik LE
    Inflamm Bowel Dis; 2017 Mar; 23(3):473-483. PubMed ID: 28221251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease.
    Targownik LE; Sexton KA; Bernstein MT; Beatie B; Sargent M; Walker JR; Graff LA
    Am J Gastroenterol; 2015 Jul; 110(7):1001-12; quiz 1013. PubMed ID: 26077178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Guthrie EA; Hamlin PJ; Ford AC
    Gastroenterology; 2018 May; 154(6):1635-1646.e3. PubMed ID: 29366841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.
    Goodhand JR; Wahed M; Mawdsley JE; Farmer AD; Aziz Q; Rampton DS
    Inflamm Bowel Dis; 2012 Dec; 18(12):2301-9. PubMed ID: 22359369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
    Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
    Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-Processed Food, Disease Activity, and Inflammation in Ulcerative Colitis: The Manitoba Living With IBD Study.
    Vagianos K; Dolovich C; Witges K; Graff LA; Bernstein CN
    Am J Gastroenterol; 2024 Jun; 119(6):1102-1109. PubMed ID: 38305329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.
    Amati L; Passeri ME; Selicato F; Mastronardi ML; Penna A; Jirillo E; Covelli V
    Immunopharmacol Immunotoxicol; 2006; 28(4):665-81. PubMed ID: 17190742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children.
    Krzesiek E
    Adv Clin Exp Med; 2015; 24(5):815-22. PubMed ID: 26768632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease.
    Lix LM; Graff LA; Walker JR; Clara I; Rawsthorne P; Rogala L; Miller N; Ediger J; Pretorius T; Bernstein CN
    Inflamm Bowel Dis; 2008 Nov; 14(11):1575-84. PubMed ID: 18512245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.